DGIdb - PAROXETINE Drug Record

PAROXETINE chembl:CHEMBL490 Approved

Alternate Names:

PEXEVA
PAXIL
BRL-29060
PAROXETINE
PAXIL [AS HYDROCHLORIDE]
(−)-(3S,4R)-4-(P-FLUOROPHENYL)-3-((3,4-(METHYLENEDIOXY)PHENOXY)METHYL)PIPERIDINE
(3S-TRANS)-3-((1,3-BENZODIOXOL-5-YLOXY)METHYL)-4-(4-FLUOROPHENYL)PIPERIDINE
PAROXETINUM
(-)-(3S,4R)-4-(P-FLUOROPHENYL)-3-((3,4-(METHYLENEDIOXY)PHENOXY)METHYL)PIPERIDINE
PAROXETINA
pubchem.compound:43815
chembl:CHEMBL490
drugbank:00715
chemidplus:61869-08-7
rxcui:32937

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antidepressant
Drug Class	antidepressive agents, second-generation
Year of Approval	1992
Drug Categories	agents producing tachycardia
Drug Categories	anticholinergic agents
Drug Categories	central nervous system depressants
Drug Categories	cytochrome p-450 cyp1a2 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp1a2 substrates
Drug Categories	cytochrome p-450 cyp2b6 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c19 inhibitors
Drug Categories	cytochrome p-450 cyp2c19 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c19 substrates
Drug Categories	cytochrome p-450 cyp2c9 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a inhibitors
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 substrates
Drug Categories	drugs causing inadvertant photosensitivity
Drug Categories	hypoglycemia-associated agents
Drug Categories	muscarinic antagonists
Drug Categories	p-glycoprotein inhibitors
Drug Categories	photosensitizing agents
Drug Categories	serotonergic drugs shown to increase risk of serotonin syndrome

(5 More Sources)

Publications:

Murata Y et al., 2010, Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome., J Clin Psychopharmacol
Sugai T et al., 2006, The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine., Pharmacogenomics J
Murphy GM Jr et al., 2003, Pharmacogenetics of antidepressant medication intolerance., Am J Psychiatry
Wilkie MJ et al., 2009, Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy., Pharmacogenomics J
Foster RH et al., 1997, Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder., CNS Drugs
Meyer et al., 2001, The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study., Am J Psychiatry
Bixo et al., 2001, Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment., Psychoneuroendocrinology
Newcombe F et al., 1969, Alkaloids of the leaves of Voacanga schweinfurthii Stapf., Planta Med
Tanaka M et al., 2008, Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea., Int J Neuropsychopharmacol
Kato M et al., 2009, 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients., Psychiatry Res
Yang Z et al., 2012, Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population., Gen Hosp Psychiatry
Kurose K et al., 2012, Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression., Psychiatry Res
Huang X et al., 2013, ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients., Pharmacogenomics
Uhr M et al., 2008, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression., Neuron
Perroud N et al., 2011, Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample., Pharmacogenomics
Breitenstein B et al., 2016, Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study., J Psychiatr Res
de Klerk OL et al., 2013, ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder., Pharmacogenomics J
Wang XC et al., 2014, Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a Chinese population., Ther Drug Monit
Benedetti F et al., 2009, The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting., Psychopharmacology (Berl)
Nemeroff et al., 2003, Neuropharmacology of paroxetine., Psychopharmacol Bull
Gilmor et al., 2002, Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine., Am J Psychiatry
Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
Rubin, 2000, Paroxetine binding to the rat norepinephrine transporter in vivo., Biol. Psychiatry
Kirchheiner J et al., 2008, Genetic variants in FKBP5 affecting response to antidepressant drug treatment., Pharmacogenomics
Zou YF et al., 2010, Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders., Neurosci Lett
Sarginson JE et al., 2010, FKBP5 polymorphisms and antidepressant response in geriatric depression., Am J Med Genet B Neuropsychiatr Genet
Binder EB et al., 2004, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment., Nat Genet
Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
Papiol S et al., 2007, Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment., J Affect Disord
Hiemke C, 1994, [Paroxetine: pharmacokinetics and pharmacodynamics]., Fortschr Neurol Psychiatr
Fujishiro J et al., 2002, Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine., Eur J Pharmacol
Gray SL et al., 2016, Anticholinergic medication use and dementia: latest evidence and clinical implications., Ther Adv Drug Saf
Cusack et al., 1994, Binding of antidepressants to human brain receptors: focus on newer generation compounds., Psychopharmacology (Berl.)
Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport
Drago A et al., 2008, 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies., Int J Neuropsychopharmacol
Kato M et al., 2009, Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder., Am J Med Genet B Neuropsychiatr Genet
Baune BT et al., 2008, Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?, Neurosci Lett
Ishiguro S et al., 2011, Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder., Eur J Clin Pharmacol
Yevtushenko OO et al., 2010, Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism., J Affect Disord
Glubb DM et al., 2010, Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine., Pharmacogenomics J
Musil R et al., 2013, No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression., Eur Arch Psychiatry Clin Neurosci
Yoshimura R et al., 2011, The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients., Prog Neuropsychopharmacol Biol Psychiatry
Murphy GM Jr et al., 2013, BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression., Pharmacogenet Genomics
Domschke K et al., 2010, Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response., Int J Neuropsychopharmacol
Wang P et al., 2018, Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients., Eur J Clin Pharmacol
Zou YF et al., 2010, Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients., Neuropsychobiology
Arias B et al., 2013, TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression., Neuropsychobiology
Lin KM et al., 2010, CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine., Pharmacogenomics
Dobrinas M et al., 2011, Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility., Clin Pharmacol Ther
Preuss et al., 2000, Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity., Psychiatry Res
Wihlbäck et al., 2001, Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding., Obstet Gynecol
Davis BA et al., 2016, Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter., Sci Rep
Scholze et al., 2000, Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter., J. Pharmacol. Exp. Ther.
Pollock et al., 2000, Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression., Neuropsychopharmacology
Haughey et al., 2000, The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia., J. Neurochem.
Tsuchimine S et al., 2012, DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study., J Clin Psychopharmacol
Thomas DR et al., 1987, Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor., Psychopharmacology (Berl)
Westenberg HG et al., 2006, Tolerability and safety of fluvoxamine and other antidepressants., Int J Clin Pract
Kobayashi K et al., 2012, Chronic fluoxetine selectively upregulates dopamine D₁-like receptors in the hippocampus., Neuropsychopharmacology
Ouk K et al., 2018, Chronic paroxetine treatment prevents disruption of methamphetamine-sensitive circadian oscillator in a transgenic mouse model of Huntington's disease., Neuropharmacology
Guo S et al., 2017, Impact of paroxetine on proximal β-adrenergic receptor signaling., Cell Signal
Peng L et al., 2014, Fluoxetine and all other SSRIs are 5-HT2B Agonists - Importance for their Therapeutic Effects., Curr Neuropharmacol
Zhang S et al., 2010, 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'., Neuron Glia Biol
Hertz L et al., 2015, Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift., Front Behav Neurosci

PAROXETINE FKBP5

Interaction Score: 1.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18597649 21449676 20709156 19676097 15565110 23733030 17467808

Sources:
PharmGKB
PAROXETINE MDGA2

Interaction Score: 1.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22445761

Sources:
PharmGKB
PAROXETINE REEP5

Interaction Score: 0.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22795047

Sources:
PharmGKB
PAROXETINE SRP19

Interaction Score: 0.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22795047

Sources:
PharmGKB
PAROXETINE P2RX4

Interaction Score: 0.56

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Antagonist

PMIDs:
None found

Sources:
GuideToPharmacology
PAROXETINE TPH1

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19590397 23221997 23733030

Sources:
PharmGKB
PAROXETINE ADM

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19636336

Sources:
PharmGKB
PAROXETINE GDNF

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24577123

Sources:
PharmGKB
PAROXETINE HTR3B

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20075642 16534507

Sources:
PharmGKB
PAROXETINE SLC6A4

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CRx-139

Novel drug target Established target

Trial Name paroxetine hydrochloride,Paxil, Seroxat

PMIDs:
10980326 11530128 27032980 10869387 23338224 9537821 11027924 10987842

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology
PAROXETINE BDNF

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22965830 21338649 23733030 23619509 19236730 29748862 20016225

Sources:
PharmGKB
PAROXETINE SLC6A2

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
14566196 12359676 9537821 11203183

Sources:
DrugBank
PAROXETINE HTR1A

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19590397 18047755 18484082 18387740 21688171 19800133 23733030

Sources:
PharmGKB DrugBank
PAROXETINE HTR2A

Interaction Score: 0.09

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
14514498 18253134 23338224 11136637 11403977 5821956 17697394 19361869

Sources:
PharmGKB DrugBank
PAROXETINE COMT

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18989660

Sources:
PharmGKB
PAROXETINE HTR2B

Interaction Score: 0.08

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
25342944 20846463 25750618

Sources:
DrugBank
PAROXETINE CHRM1

Interaction Score: 0.05

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

PMIDs:
7959522 12421645 27695623 7855217

Sources:
DrugBank
PAROXETINE HTR1B

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21449676

Sources:
PharmGKB
PAROXETINE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24192121 18215618 21449676 26704739 22641028

Sources:
PharmGKB
PAROXETINE DRD3

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22926616

Sources:
PharmGKB
PAROXETINE DRD1

Interaction Score: 0.03

Interaction Types & Directionality:

other/unknown

Interaction Info:

PMIDs:
23338224 22278095

Sources:
DrugBank
PAROXETINE ADRB1

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
28711716

Sources:
DrugBank
PAROXETINE ADRA2A

Interaction Score: 0.02

Interaction Types & Directionality:

binder

Interaction Info:

PMIDs:
2962217

Sources:
DrugBank
PAROXETINE DRD2

Interaction Score: 0.02

Interaction Types & Directionality:

other/unknown

Interaction Info:

PMIDs:
29274752 23338224

Sources:
DrugBank
PAROXETINE ADRA1A

Interaction Score: 0.02

Interaction Types & Directionality:

binder

Interaction Info:

PMIDs:
2962217

Sources:
DrugBank
PAROXETINE HRH1

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16620364

Sources:
DrugBank
PAROXETINE CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PAROXETINE MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAROXETINE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21121774 21593735

Sources:
PharmGKB
PAROXETINE ATXN2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAROXETINE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA
PAROXETINE EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAROXETINE AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PAROXETINE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

DrugBank: DB00715

Version: 5.1.7

Alternate Names:

PAROXETINE DrugBank Drug Name

61869-08-7 CAS Number

Act Paroxetine Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Foster RH et al., 1997, Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder., CNS Drugs

Meyer et al., 2001, The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study., Am J Psychiatry

Bixo et al., 2001, Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment., Psychoneuroendocrinology

TEND: PAROXETINE
- Version: 01-August-2011
Alternate Names:

PAROXETINE Primary Drug Name

Drug Info:

Year of Approval 1992

Drug Class antidepressive agents, second-generation

Publications:
TdgClinicalTrial: PAROXETINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antidepressant

Drug Class Small Molecule

FDA Approval approved

Publications:

PharmGKB: paroxetine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Murata Y et al., 2010, Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome., J Clin Psychopharmacol

Sugai T et al., 2006, The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine., Pharmacogenomics J

Kurose K et al., 2012, Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression., Psychiatry Res

TTD: Paroxetine
- Version: 2020.06.01
Alternate Names:

D06GDY TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178101492
- Version: 29-September-2020
Alternate Names:

PAROXETINE GuideToPharmacology Ligand Name

Drug Info:

Publications:
DTC: PAROXETINE
- Version: 02-September-2020
Alternate Names:

CHEMBL490 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL490
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Paroxetine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Antagonist

Trial Name	CRx-139
Novel drug target	Established target
Trial Name	paroxetine hydrochloride,Paxil, Seroxat

PAROXETINE	DrugBank Drug Name
61869-08-7	CAS Number
Act Paroxetine	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

antagonist (inhibitory)
inhibitor (inhibitory)

PAROXETINE Drug Record

PAROXETINE chembl:CHEMBL490 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18597649 21449676 20709156 19676097 15565110 23733030 17467808

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22445761

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22795047

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22795047

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Antagonist

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19590397 23221997 23733030

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19636336

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24577123

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20075642 16534507

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name CRx-139 Novel drug target Established target Trial Name paroxetine hydrochloride,Paxil, Seroxat

PMIDs: 10980326 11530128 27032980 10869387 23338224 9537821 11027924 10987842

Sources: TEND TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22965830 21338649 23733030 23619509 19236730 29748862 20016225

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 14566196 12359676 9537821 11203183

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19590397 18047755 18484082 18387740 21688171 19800133 23733030

Sources: PharmGKB DrugBank

Interaction Types & Directionality: agonist (activating)

Interaction Info:

PMIDs: 14514498 18253134 23338224 11136637 11403977 5821956 17697394 19361869

Sources: PharmGKB DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18989660

Sources: PharmGKB

Interaction Types & Directionality: agonist (activating)

Interaction Info:

PMIDs: 25342944 20846463 25750618

Sources: DrugBank

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info:

PMIDs: 7959522 12421645 27695623 7855217

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21449676

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24192121 18215618 21449676 26704739 22641028

Interaction Types & Directionality:

n/a

PMIDs:
18597649 21449676 20709156 19676097 15565110 23733030 17467808

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22445761

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22795047

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22795047

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Antagonist

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
19590397 23221997 23733030

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19636336

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24577123

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20075642 16534507

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CRx-139

Novel drug target Established target

Trial Name paroxetine hydrochloride,Paxil, Seroxat

PMIDs:
10980326 11530128 27032980 10869387 23338224 9537821 11027924 10987842

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
22965830 21338649 23733030 23619509 19236730 29748862 20016225

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
14566196 12359676 9537821 11203183

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
19590397 18047755 18484082 18387740 21688171 19800133 23733030

Sources:
PharmGKB DrugBank

Interaction Types & Directionality:

agonist (activating)

PMIDs:
14514498 18253134 23338224 11136637 11403977 5821956 17697394 19361869

Sources:
PharmGKB DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
18989660

Sources:
PharmGKB

Interaction Types & Directionality:

agonist (activating)

PMIDs:
25342944 20846463 25750618

Sources:
DrugBank

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

PMIDs:
7959522 12421645 27695623 7855217

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
21449676

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24192121 18215618 21449676 26704739 22641028

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22926616

Sources:
PharmGKB

Interaction Types & Directionality:

other/unknown

PMIDs:
23338224 22278095

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
28711716

Sources:
DrugBank

Interaction Types & Directionality:

binder

PMIDs:
2962217

Sources:
DrugBank

Interaction Types & Directionality:

other/unknown

PMIDs:
29274752 23338224

Sources:
DrugBank

Interaction Types & Directionality:

binder

PMIDs:
2962217

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
16620364

Sources:
DrugBank